EGFR and non-small cell lung carcinoma: This mutation has been found in NSCLC [7-9]. Across three studies, patients with NSCLC harboring the EGFR L833V mutation in combination with the TKI-sensitizing EGFR L858R, G719A, or H835L mutations had a partial response (two of five), complete response (one of five), or stable disease upon treatment with gefitinib [7-9].